Biotechnology
Compare Stocks
5 / 10Stock Comparison
DBVT vs PRGO vs HLN vs ALKS vs JNJ
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Biotechnology
Drug Manufacturers - General
DBVT vs PRGO vs HLN vs ALKS vs JNJ — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Biotechnology | Drug Manufacturers - General |
| Market Cap | $1712.35T | $1.61B | $41.45B | $5.90B | $536.23B |
| Revenue (TTM) | $0.00 | $4.18B | $22.01B | $1.56B | $92.15B |
| Net Income (TTM) | $-168M | $-1.82B | $3.18B | $153M | $25.12B |
| Gross Margin | — | 34.2% | 63.9% | 65.4% | 68.1% |
| Operating Margin | — | -4.1% | 21.4% | 12.3% | 26.1% |
| Forward P/E | — | 5.6x | 22.2x | 24.8x | 19.2x |
| Total Debt | $22M | $3.97B | $8.59B | $70M | $36.63B |
| Cash & Equiv. | $194M | $532M | $1.32B | $1.12B | $24.11B |
DBVT vs PRGO vs HLN vs ALKS vs JNJ — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 22 | May 26 | Return |
|---|---|---|---|
| DBV Technologies S.… (DBVT) | 100 | 78.4 | -21.6% |
| Perrigo Company plc (PRGO) | 100 | 28.0 | -72.0% |
| Haleon plc (HLN) | 100 | 132.4 | +32.4% |
| Alkermes plc (ALKS) | 100 | 138.3 | +38.3% |
| Johnson & Johnson (JNJ) | 100 | 127.5 | +27.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DBVT vs PRGO vs HLN vs ALKS vs JNJ
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DBVT ranks third and is worth considering specifically for momentum.
- +110.4% vs PRGO's -51.2%
PRGO is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Lower P/E (5.6x vs 19.2x)
- 9.8% yield, 10-year raise streak, vs JNJ's 2.2%, (2 stocks pay no dividend)
HLN is the clearest fit if your priority is valuation efficiency.
- PEG 2.63 vs JNJ's 34.17
ALKS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
JNJ carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 36 yrs, beta 0.06, yield 2.2%
- Rev growth 4.3%, EPS growth -57.8%, 3Y rev CAGR 4.1%
- 132.3% 10Y total return vs ALKS's -11.0%
- Beta 0.06, yield 2.2%, current ratio 1.11x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 4.3% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (5.6x vs 19.2x) | |
| Quality / Margins | 27.3% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 0.06 vs DBVT's 1.26 | |
| Dividends | 9.8% yield, 10-year raise streak, vs JNJ's 2.2%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +110.4% vs PRGO's -51.2% | |
| Efficiency (ROA) | 13.0% ROA vs DBVT's -89.0% |
DBVT vs PRGO vs HLN vs ALKS vs JNJ — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
DBVT vs PRGO vs HLN vs ALKS vs JNJ — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JNJ leads in 3 of 6 categories
PRGO leads 1 • DBVT leads 0 • HLN leads 0 • ALKS leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JNJ leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JNJ and DBVT operate at a comparable scale, with $92.1B and $0 in trailing revenue. JNJ is the more profitable business, keeping 27.3% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $4.2B | $22.0B | $1.6B | $92.1B |
| EBITDAEarnings before interest/tax | -$112M | $58M | $5.3B | $212M | $31.4B |
| Net IncomeAfter-tax profit | -$168M | -$1.8B | $3.2B | $153M | $25.1B |
| Free Cash FlowCash after capex | -$151M | $108M | $3.1B | $392M | $19.1B |
| Gross MarginGross profit ÷ Revenue | — | +34.2% | +63.9% | +65.4% | +68.1% |
| Operating MarginEBIT ÷ Revenue | — | -4.1% | +21.4% | +12.3% | +26.1% |
| Net MarginNet income ÷ Revenue | — | -43.5% | +14.5% | +9.8% | +27.3% |
| FCF MarginFCF ÷ Revenue | — | +2.6% | +14.2% | +25.1% | +20.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -7.2% | -0.4% | +28.2% | +6.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +91.5% | -56.4% | +18.8% | -4.1% | +91.0% |
Valuation Metrics
PRGO leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 19.0x trailing earnings, HLN trades at a 51% valuation discount to JNJ's 38.4x P/E. Adjusting for growth (PEG ratio), HLN offers better value at 2.25x vs JNJ's 34.17x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1712.35T | $1.6B | $41.4B | $5.9B | $536.2B |
| Enterprise ValueMkt cap + debt − cash | $1712.35T | $5.1B | $51.3B | $4.9B | $548.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.76x | -1.14x | 19.01x | 24.76x | 38.43x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.56x | 22.22x | — | 19.20x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.25x | — | 34.17x |
| EV / EBITDAEnterprise value multiple | — | 7.42x | 13.62x | 17.25x | 18.61x |
| Price / SalesMarket cap ÷ Revenue | — | 0.38x | 2.83x | 4.00x | 6.04x |
| Price / BookPrice ÷ Book value/share | 0.66x | 0.55x | 1.87x | 3.28x | 7.56x |
| Price / FCFMarket cap ÷ FCF | — | 11.12x | 15.47x | 12.28x | 27.02x |
Profitability & Efficiency
JNJ leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
JNJ delivers a 31.7% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), HLN scores 8/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -130.2% | -50.7% | +19.9% | +8.8% | +31.7% |
| ROA (TTM)Return on assets | -89.0% | -19.8% | +10.0% | +5.4% | +13.0% |
| ROICReturn on invested capital | — | +3.7% | +7.6% | +18.9% | +20.7% |
| ROCEReturn on capital employed | -145.7% | +4.3% | +8.6% | +14.2% | +17.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 8 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.13x | 1.35x | 0.52x | 0.04x | 0.51x |
| Net DebtTotal debt minus cash | -$172M | $3.4B | $7.3B | -$1.0B | $12.5B |
| Cash & Equiv.Liquid assets | $194M | $532M | $1.3B | $1.1B | $24.1B |
| Total DebtShort + long-term debt | $22M | $4.0B | $8.6B | $70M | $36.6B |
| Interest CoverageEBIT ÷ Interest expense | -189.82x | -7.20x | 7.80x | 32.30x | 48.23x |
Total Returns (Dividends Reinvested)
JNJ leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors JNJ at 13.5% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +4.9% | -13.5% | -5.6% | +25.3% | +7.9% |
| 1-Year ReturnPast 12 months | +110.4% | -51.2% | -11.7% | +16.5% | +44.8% |
| 3-Year ReturnCumulative with dividends | +19.7% | -58.1% | +10.4% | +14.5% | +46.3% |
| 5-Year ReturnCumulative with dividends | -69.1% | -60.1% | +31.7% | +60.9% | +46.1% |
| 10-Year ReturnCumulative with dividends | -87.0% | -77.7% | +31.7% | -11.0% | +132.3% |
| CAGR (3Y)Annualised 3-year return | +6.2% | -25.2% | +3.4% | +4.6% | +13.5% |
Risk & Volatility
Evenly matched — ALKS and JNJ each lead in 1 of 2 comparable metrics.
Risk & Volatility
JNJ is the less volatile stock with a 0.06 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.26x | 1.18x | 0.06x | 1.06x | 0.06x |
| 52-Week HighHighest price in past year | $26.18 | $28.44 | $11.42 | $36.60 | $251.71 |
| 52-Week LowLowest price in past year | $7.53 | $9.23 | $8.71 | $25.17 | $146.12 |
| % of 52W HighCurrent price vs 52-week peak | +76.3% | +41.2% | +81.5% | +96.7% | +88.4% |
| RSI (14)Momentum oscillator 0–100 | 48.1 | 60.9 | 36.0 | 60.2 | 37.1 |
| Avg Volume (50D)Average daily shares traded | 252K | 3.4M | 8.0M | 2.3M | 7.0M |
Analyst Outlook
Evenly matched — PRGO and JNJ each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: DBVT as "Buy", PRGO as "Hold", HLN as "Buy", ALKS as "Buy", JNJ as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 9.6% for HLN (target: $10). For income investors, PRGO offers the higher dividend yield at 9.81% vs HLN's 1.94%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $46.33 | $20.00 | $10.20 | $44.00 | $249.27 |
| # AnalystsCovering analysts | 15 | 36 | 4 | 28 | 40 |
| Dividend YieldAnnual dividend ÷ price | — | +9.8% | +1.9% | — | +2.2% |
| Dividend StreakConsecutive years of raises | 0 | 10 | 2 | 0 | 36 |
| Dividend / ShareAnnual DPS | — | $1.15 | $0.13 | — | $4.87 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +2.1% | +0.5% | +0.5% |
JNJ leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 1 (Valuation Metrics). 2 tied.
DBVT vs PRGO vs HLN vs ALKS vs JNJ: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DBVT or PRGO or HLN or ALKS or JNJ a better buy right now?
For growth investors, Johnson & Johnson (JNJ) is the stronger pick with 4.
3% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Haleon plc (HLN) offers the better valuation at 19. 0x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DBVT or PRGO or HLN or ALKS or JNJ?
On trailing P/E, Haleon plc (HLN) is the cheapest at 19.
0x versus Johnson & Johnson at 38. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Haleon plc wins at 2. 63x versus Johnson & Johnson's 34. 17x.
03Which is the better long-term investment — DBVT or PRGO or HLN or ALKS or JNJ?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: JNJ returned +132. 3% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DBVT or PRGO or HLN or ALKS or JNJ?
By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.
06β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 2106% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — DBVT or PRGO or HLN or ALKS or JNJ?
By revenue growth (latest reported year), Johnson & Johnson (JNJ) is pulling ahead at 4.
3% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Haleon plc grew EPS 12. 5% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DBVT or PRGO or HLN or ALKS or JNJ?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DBVT or PRGO or HLN or ALKS or JNJ more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Haleon plc (HLN) is the more undervalued stock at a PEG of 2. 63x versus Johnson & Johnson's 34. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Perrigo Company plc (PRGO) trades at 5. 6x forward P/E versus 22. 2x for Haleon plc — 16. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — DBVT or PRGO or HLN or ALKS or JNJ?
In this comparison, PRGO (9.
8% yield), JNJ (2. 2% yield), HLN (1. 9% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is DBVT or PRGO or HLN or ALKS or JNJ better for a retirement portfolio?
For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
06), 2. 2% yield, +132. 3% 10Y return). Both have compounded well over 10 years (JNJ: +132. 3%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DBVT and PRGO and HLN and ALKS and JNJ?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: DBVT is a mega-cap quality compounder stock; PRGO is a small-cap income-oriented stock; HLN is a mid-cap quality compounder stock; ALKS is a small-cap quality compounder stock; JNJ is a large-cap quality compounder stock. PRGO, HLN, JNJ pay a dividend while DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.